Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia

X
Trial Profile

A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 12 Nov 2020 According to Sunovion Pharmaceuticals media release, the European Medicines Agency (EMA) has approved Latuda (lurasidone) for the treatment of Adolescent Schizophrenia in patients starting from 13 years of age.
    • 15 Sep 2020 Results (n=537) of post-hoc pooled analysis assessing safety and efficacy of Lurasidone from six double blind, placebo-controlled, 6 weeks clinical studies in adolescents and young adults with schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
    • 02 May 2018 According to a Sunovion Pharmaceuticals media release, data from the interim analysis of the 24-Month, open-label extension study will be presented at the American Psychiatric Association (APA) Annual Meeting (2018).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top